R Zarth1, M Ehmer, H-B Sittig. 1. Abteilung für Anästhesie und Intensivmedizin, Zollernalb-Klinikum, Akademisches Lehrkrankenhaus der Universität Tübingen, Tübinger Str. 20/3 , 72336 Balingen, Deutschland. ralf.zarth@zollernalb-klinikum.de
Abstract
BACKGROUND: In a non-interventional study the efficacy and tolerability of oral transmucosal fentanyl citrate (OTFC) was studied in patients with opioid-treated cancer pain suffering from breakthrough pain. PATIENTS AND METHODS: The prospective multicenter observational trial included 406 patients. For 3-4 months, efficacy of OTFC treatment for breakthrough pain was documented using a numerical analog pain intensity scale (NAS). Further, OTFC therapy was rated and adverse events were recorded. RESULTS: With application of oral transmucosal fentanyl citrate median pain intensity fell from NAS 8 points at the beginning to NAS 2 points at the end of the study. The median effective dosage was 400 g. Tolerability was rated as good or very good by 87.5% of the patients. CONCLUSION: Oral transmucosal fentanyl citrate is a safe and effective treatment for breakthrough pain in chronic cancer-related pain.
BACKGROUND: In a non-interventional study the efficacy and tolerability of oral transmucosal fentanyl citrate (OTFC) was studied in patients with opioid-treated cancer pain suffering from breakthrough pain. PATIENTS AND METHODS: The prospective multicenter observational trial included 406 patients. For 3-4 months, efficacy of OTFC treatment for breakthrough pain was documented using a numerical analog pain intensity scale (NAS). Further, OTFC therapy was rated and adverse events were recorded. RESULTS: With application of oral transmucosal fentanyl citrate median pain intensity fell from NAS 8 points at the beginning to NAS 2 points at the end of the study. The median effective dosage was 400 g. Tolerability was rated as good or very good by 87.5% of the patients. CONCLUSION: Oral transmucosal fentanyl citrate is a safe and effective treatment for breakthrough pain in chronic cancer-related pain.
Authors: P H Coluzzi; L Schwartzberg; J D Conroy; S Charapata; M Gay; M A Busch; J Chavez; J Ashley; D Lebo; M McCracken; R K Portenoy Journal: Pain Date: 2001-03 Impact factor: 6.961
Authors: R K Portenoy; R Payne; P Coluzzi; J W Raschko; A Lyss; M A Busch; V Frigerio; J Ingham; D B Loseth; E Nordbrock; M Rhiner Journal: Pain Date: 1999-02 Impact factor: 6.961
Authors: J B Streisand; J R Varvel; D R Stanski; L Le Maire; M A Ashburn; B I Hague; S D Tarver; T H Stanley Journal: Anesthesiology Date: 1991-08 Impact factor: 7.892